

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (Cancelled)

Claim 32 (Currently Amended) A therapeutic mammalian non-plasmocyte cell genetically modified with a nucleic acid sequence, wherein the nucleic acid sequence comprises a nucleotide sequence coding for a native, unmodified therapeutic antibody molecule:

- (a) wherein the nucleotide sequence coding for the antibody molecule is operably linked to a promoter for expressing the nucleotide sequence encoding the antibody molecule in the mammalian non-plasmocyte cell, ~~and;~~
- (b) wherein the nucleotide sequence encoding the antibody is not modified;
- (b c) wherein the ~~nucleic acid~~ nucleotide sequence comprises a sequence for termination of the transcription, situated downstream from the sequence coding for the antibody molecule; ~~and a sequence permitting the secretion of the antibody molecule from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal;~~ and
- (d) wherein the antibody is secreted into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal.

~~wherein the genetically modified mammalian non-plasmocyte cell, when administered to a mammal, produces the antibody molecule in vivo and is suitable for remaining in the mammal for several months.~~

Claims 33-34 (Cancelled)

Claim 35 (Currently Amended) The therapeutic cell of claim 32, wherein the nucleic acid sequence is inserted in a vector.

Claim 36 (Currently Amended) The therapeutic cell of claim 32, wherein the vector is a viral vector.

Claim 37 (Currently Amended) The therapeutic cell of claim 32, wherein the cell is selected from the group consisting of: keratinocyte, hepatocyte, fibroblast, myoblast, endothelial cell, and hematopoietic cell.

Claim 38 (Currently Amended) The therapeutic cell of claim 32, wherein the antibody is directed against a tumor cell antigen.

Claim 39 (Currently Amended) The therapeutic cell of claim 32, wherein the antibody is directed against a virus.

Claim 40 (Currently Amended) A method of making a therapeutic mammalian non-plasmocyte cell comprising a nucleic acid sequence ~~containing~~ further comprising a polynucleotide coding for a ~~native, unmodified~~ therapeutic antibody ~~polypeptide~~, comprising the step of transferring upon transfection at least one nucleic acid sequence comprising a polynucleotide coding for said ~~native, unmodified~~ the therapeutic antibody ~~polypeptide~~;

- (a) wherein the coding polynucleotide is operably linked to a promoter for expressing the polynucleotide encoding the antibody ~~polypeptide~~ in the mammalian non-plasmocyte cell; and
- (b) wherein the polynucleotide sequence encoding the antibody is not modified; and
- (b-c) wherein the translation of the coding polynucleotide ~~is operably linked to a polynucleotide element required for results in~~ the secretion of the antibody ~~polypeptide~~ from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell.

Claim 41 (Cancelled)

Claim 42 (Currently Amended) A method for delivering an antibody molecule to the blood system of a host mammal, comprising: implanting a therapeutic cell into a mammal;

- (a) wherein the implanted cell is a mammalian non-plasmocyte cell genetically modified with a nucleic acid sequence, wherein the nucleic acid sequence comprises a nucleotide sequence coding for a ~~native, unmodified~~ therapeutic antibody molecule;
- (b) wherein the nucleotide sequence coding for the ~~native, unmodified~~ therapeutic antibody molecule is operably linked to a promoter for expressing said the nucleotide sequence coding the therapeutic antibody ~~molecule~~ in the mammalian non-plasmocyte cell; and
- (c) wherein the nucleotide sequence encoding the antibody molecule is not modified;
- (ed) wherein the nucleic acid comprises a sequence for termination of the transcription, situated downstream from the sequence coding for an therapeutic antibody molecule; and
- (e) wherein translation of the nucleotide and a sequence results in permitting the secretion of said the therapeutic antibody molecule from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal.

Claim 43 (New) The method of claim 42, wherein the therapeutic antibody molecule is selected from the group consisting of: a single antibody heavy chain, a single antibody light chain, and an antibody molecule comprising a heavy chain and a light chain, or fragments thereof.